NEW YORK, April 17, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Arca Biopharma Inc. (NASDAQ: ABIO), Great Basin Scientific Inc. (NASDAQ: GBSN), Corium International Inc. (NASDAQ: CORI), Alphatec Holdings Inc. (NASDAQ: ATEC), and Akers Biosciences Inc. (NASDAQ: AKER). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
ABIO Research Report: ( http://get.analystsreview.com/pdf/?c=Arca%20Biopharma&d=17-Apr-2015&s=ABIO ),
GBSN Research Report: ( http://get.analystsreview.com/pdf/?c=Great%20Basin&d=17-Apr-2015&s=GBSN ),
CORI Research Report: ( http://get.analystsreview.com/pdf/?c=Corium%20International&d=17-Apr-2015&s=CORI ),
ATEC Research Report: ( http://get.analystsreview.com/pdf/?c=Alphatec%20Holdings&d=17-Apr-2015&s=ATEC ),
AKER Research Report: ( http://get.analystsreview.com/pdf/?c=Akers%20Biosciences&d=17-Apr-2015&s=AKER ).
Analyst Update: Progress Updates, Appointments, andDistribution Expansions
Reviewed by: Rohit Tuli, CFA®
US stocks ended marginally lower on Thursday, as worries about upcoming corporate earnings reports offset enthusiasm about a trio of soaring Wall Street debuts. The Dow Jones industrial average fell 6.84 points, or 0.04%, to end at 18,105.77; the S&P 500 lost 1.64 points, or 0.08%, to 2,104.99; and the Nasdaq Composite dropped 3.23 points, or 0.06%, to 5,007.79. European markets finished broadly lower on Thursday with growing concerns about Greece's debt situation prompting investors to take some profits after the previous session's 14-year highs. The DAX closed 1.94% lower, France's CAC 40 declined by 0.57% and London's FTSE 100 declined by 0.51%. The pan-European FTSEurofirst 300 index closed 0.9% lower at 1,635.76 points. Chinese shares rebounded on stimulus hopes a day after gloomy first-quarter economic numbers with the Shanghai composite index rising 2.1% to 4,168.85, while other Asian benchmarks were mixed.
Shares of ARCA Biopharma Inc. rose 13.3% on April 13, 2015 to close at $0.95 after the Company announced that it has received US FDA Fast Track designation for its lead pipeline candidate Genarco TM, which is currently being evaluated as a potential treatment for atrial fibrillation in a genetically-defined heart failure (HFREF) population in GENETIC-AF, a Phase 2B/3 adaptive design clinical trial.
Shares of Great Basin Scientific Inc. rose 42.5% to close at $4.2 on April 13, 2015. On the same morning, the Company announced that it currently has 101 revenue-generating customers as against 84 in the previous quarter. Customer evaluations, which represent the Company's sales pipeline, also saw a matched increase of 20% over the fourth quarter of 2014 from 43 active and scheduled evaluations to 52 at the end of Q1 2015.
On the first of this month, Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced the appointment of Eric Bjerkholt to the Board and as Chair of the Board's Audit Committee.
Alphatec Holdings Inc., the parent company of Alphatec Spine, Inc., recently announced financial results for the fourth quarter and full year ended December 31, 2014. The stock of the Company closed up 7.4% higher on the day following the results, which came in during after-hours on February 26, 2015.
Akers Biosciences Inc shares rose 2% to close at $5.1 on 13th April. On the same morning, Nasdaq's Globe Newswire published that the Company has added six new distributors in nine countries of Europe, Middle East and Africa to market its rapid tests for heparin-induced thrombocytopenia ("HIT").
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review